On December 7, 2023, Robert Gorman, a Class II director designated by Ampersand 2018 Limited Partnership to the board of directors of Interpace Biosciences, Inc. provided notice to the Company of his resignation as a director and as Chairman of the Board, including as a member of the Board?s Regulatory Compliance Committee, effective immediately. Mr. Gorman?s notice was not the result of any disagreement with the Company on any matters relating to the Company?s operations, policies or practices. However, Mr. Gorman disagreed with the timing of the proposed change in his position from Executive Chairman to Chairman and the reduction in compensation thereunder.